Roche的新药Fenebrutinib 显示了停止重复多发性硬化症的有力前景。 Roche's new drug fenebrutinib shows strong promise in halting relapsing multiple sclerosis.

Roche的实验药物Fenebrutinib在治疗复发性多发性硬化症(RMS)方面显示出可喜的成果,数据显示在两年内几乎完全抑制了疾病活动和残疾。 Roche's experimental drug fenebrutinib shows promising results in treating relapsing multiple sclerosis (RMS), with data indicating a near-total suppression of disease activity and disability progression over two years. 患者年复发率极低,没有残疾升级。 Patients experienced an extremely low annual relapse rate and no disability progression. 该药是布鲁顿的暴躁性血酶抑制剂,目前已进入第三阶段试验阶段,预计到2025年底将取得结果。 The drug, a Bruton's tyrosine kinase inhibitor, is now in Phase III trials, with results anticipated by year-end 2025.